Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease
Copyright © 2021 Italian Federation of Cardiology - I.F.C. All rights reserved..
AIMS: Chronic obstructive pulmonary disease (COPD) is a frequent comorbidity in patients with heart failure (HF). We assessed the influence of COPD on circulating levels and prognostic value of three HF biomarkers: N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hs-TnT), and soluble suppression of tumorigenesis-2 (sST2).
METHODS: Individual data from patients with chronic HF, known COPD status, NT-proBNP and hs-TnT values (n = 8088) were analysed. A subgroup (n = 3414) had also sST2 values.
RESULTS: Patients had a median age of 66 years (interquartile interval 57-74), 77% were men and 82% had HF with reduced ejection fraction. NT-proBNP, hs-TnT and sST2 were 1207 ng/l (487-2725), 17 ng/l (9-31) and 30 ng/ml (22-44), respectively. Patients with COPD (n = 1249, 15%) had higher NT-proBNP (P = 0.042) and hs-TnT (P < 0.001), but not sST2 (P = 0.165). Over a median 2.0-year follow-up (1.5-2.5), 1717 patients (21%) died, and 1298 (16%) died from cardiovascular causes; 2255 patients (28%) were hospitalized for HF over 1.8 years (0.9-2.1). NT-proBNP, hs-TnT and sST2 predicted the three end points regardless of COPD status. The best cut-offs from receiver-operating characteristics analysis were higher in patients with COPD than in those without. Patients with all three biomarkers higher than or equal to end-point- and COPD-status-specific cut-offs were also those with the worst prognosis.
CONCLUSIONS: Among patients with HF, those with COPD have higher NT-proBNP and hs-TnT, but not sST2. All these biomarkers yield prognostic significance regardless of the COPD status.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Journal of cardiovascular medicine (Hagerstown, Md.) - 23(2022), 1 vom: 01. Jan., Seite 28-36 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vergaro, Giuseppe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
114471-18-0 |
|---|
| Anmerkungen: |
Date Completed 15.02.2022 Date Revised 17.08.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2459/JCM.0000000000001281 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333764307 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333764307 | ||
| 003 | DE-627 | ||
| 005 | 20231225222324.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2459/JCM.0000000000001281 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1112.xml |
| 035 | |a (DE-627)NLM333764307 | ||
| 035 | |a (NLM)34839321 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vergaro, Giuseppe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2022 | ||
| 500 | |a Date Revised 17.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Italian Federation of Cardiology - I.F.C. All rights reserved. | ||
| 520 | |a AIMS: Chronic obstructive pulmonary disease (COPD) is a frequent comorbidity in patients with heart failure (HF). We assessed the influence of COPD on circulating levels and prognostic value of three HF biomarkers: N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hs-TnT), and soluble suppression of tumorigenesis-2 (sST2) | ||
| 520 | |a METHODS: Individual data from patients with chronic HF, known COPD status, NT-proBNP and hs-TnT values (n = 8088) were analysed. A subgroup (n = 3414) had also sST2 values | ||
| 520 | |a RESULTS: Patients had a median age of 66 years (interquartile interval 57-74), 77% were men and 82% had HF with reduced ejection fraction. NT-proBNP, hs-TnT and sST2 were 1207 ng/l (487-2725), 17 ng/l (9-31) and 30 ng/ml (22-44), respectively. Patients with COPD (n = 1249, 15%) had higher NT-proBNP (P = 0.042) and hs-TnT (P < 0.001), but not sST2 (P = 0.165). Over a median 2.0-year follow-up (1.5-2.5), 1717 patients (21%) died, and 1298 (16%) died from cardiovascular causes; 2255 patients (28%) were hospitalized for HF over 1.8 years (0.9-2.1). NT-proBNP, hs-TnT and sST2 predicted the three end points regardless of COPD status. The best cut-offs from receiver-operating characteristics analysis were higher in patients with COPD than in those without. Patients with all three biomarkers higher than or equal to end-point- and COPD-status-specific cut-offs were also those with the worst prognosis | ||
| 520 | |a CONCLUSIONS: Among patients with HF, those with COPD have higher NT-proBNP and hs-TnT, but not sST2. All these biomarkers yield prognostic significance regardless of the COPD status | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a IL1RL1 protein, human |2 NLM | |
| 650 | 7 | |a Interleukin-1 Receptor-Like 1 Protein |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 650 | 7 | |a Troponin T |2 NLM | |
| 650 | 7 | |a pro-brain natriuretic peptide (1-76) |2 NLM | |
| 650 | 7 | |a Natriuretic Peptide, Brain |2 NLM | |
| 650 | 7 | |a 114471-18-0 |2 NLM | |
| 700 | 1 | |a Aimo, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Januzzi, James L |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Richards, A Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Lam, Carolyn S P |e verfasserin |4 aut | |
| 700 | 1 | |a Latini, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Staszewsky, Lidia |e verfasserin |4 aut | |
| 700 | 1 | |a Anand, Inder S |e verfasserin |4 aut | |
| 700 | 1 | |a Ueland, Thor |e verfasserin |4 aut | |
| 700 | 1 | |a Rocca, Hans-Peter Brunner-La |e verfasserin |4 aut | |
| 700 | 1 | |a Bayes-Genis, Antoni |e verfasserin |4 aut | |
| 700 | 1 | |a Lupón, Josep |e verfasserin |4 aut | |
| 700 | 1 | |a de Boer, Rudolf A |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshihisa, Akiomi |e verfasserin |4 aut | |
| 700 | 1 | |a Takeishi, Yasuchika |e verfasserin |4 aut | |
| 700 | 1 | |a Gustafsson, Ida |e verfasserin |4 aut | |
| 700 | 1 | |a Eggers, Kai M |e verfasserin |4 aut | |
| 700 | 1 | |a Huber, Kurt |e verfasserin |4 aut | |
| 700 | 1 | |a Gamble, Greg D |e verfasserin |4 aut | |
| 700 | 1 | |a Leong, Kui Toh Gerard |e verfasserin |4 aut | |
| 700 | 1 | |a Yeo, Poh Shuan Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Ong, Hean Yee |e verfasserin |4 aut | |
| 700 | 1 | |a Jaufeerally, Fazlur |e verfasserin |4 aut | |
| 700 | 1 | |a Ng, Tze P |e verfasserin |4 aut | |
| 700 | 1 | |a Troughton, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Doughty, Robert N |e verfasserin |4 aut | |
| 700 | 1 | |a Emdin, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Passino, Claudio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cardiovascular medicine (Hagerstown, Md.) |d 2006 |g 23(2022), 1 vom: 01. Jan., Seite 28-36 |w (DE-627)NLM162293844 |x 1558-2035 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:28-36 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2459/JCM.0000000000001281 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 1 |b 01 |c 01 |h 28-36 | ||